人白介素-2基因转染对原代肾细胞癌的抑瘤作用

SUPPRESSION OF TUMORIGENICITY OF PRIMARY RENAL CELL CARCINOMA (RCC) CELLS TRANSFECTED WITH HUMAN IL -2 GENE

目的 研究转人IL 2基因对原代肾细胞癌 (RCC)细胞致瘤性的影响 ,为RCC的基因治疗提供依据。方法 将人IL 2基因与逆转录病毒载体pLNCX连接 ,转染包装细胞 ,经鉴定后 ,感染原代RCC细胞 ,用MTT法测转人IL 2基因的原代RCC的IL 2的活性 ,然后 ,将转人IL 2基因的原代RCC和未转染原代RCC分别接种裸鼠 ,观测转IL 2前后RCC细胞致瘤性的变化。结果 转人IL 2的RCC细胞上清液IL 2的生物学活性平均 2 44± 5 2U/ml,接种裸鼠后无肿瘤长出。结论 转人IL 2基因使原代RCC失去了致瘤性 ,转人IL 2基因的RCC细胞可作为瘤苗用于肾细胞癌的治疗。

Objective To study the influence on tumorigenicity of human renal cell carcinoma (RCC) cells transduced with human IL 2 gene, and to intend in forming a basis for RCC gene therapy.Methods Recombinant retroviral vector pLNC (IL 2) was constructed and transfected into the packaged cell. Primary RCC cells were infected with confirmed retrovirus, and the biological activity of rhIL 2 was tested by MTT method. Then, nude mice were injected with primary RCC cell infected with or without the hIL 2 gene, and the tumorigenecity of RCC was observed.Results The biological activity of rhIL 2 in the recombinant retrovirus supernatants was 244±52 U/ml. The nude mice injected with IL 2 gene enginerred RCC cells had no tumor growth. Conclusion The IL 2 gene engineered human RCC cells lost tumorigenicity. The primary RCC cells transduced with human IL 2 gene might be used as tumor vaccine to treat the RCC.$$$$